Immunological Diseases - BJSTR Journal

Abstract

The #natriuretic peptide system plays a critical role in the maintenance of #cardiovascular homeostasis. Since the natriuretic peptides were discovered more than 2 decades ago, B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) has become the most interesting #biomarkers in #diagnosis, risk stratification, and management of patients with heart failure (HF). More importantly, with the deepening of understanding of physiological and #pathophysiological effects of BNP, increasing biological effects of BNP has been considered to be an attractive approach for treating HF. However, treatment effects of BNP in patients with both acute and chronic HF in various clinical trials have demonstrated different results. The biology of BNP is complex, there are many important issues not yet elucidated. In this review, we will focus on the the diversity of therapeutic effects of BNP in HF and give directions for the future studies. B-type natriuretic peptide (BNP) is a circulating hormone synthesized in the cardiac ventricles in response to ventricular wall stretch resulting from pressure overload [1]. During the processing of BNP production, it is synthesized as a 134-residue preprohormone, which is subsequently cleaved to form a 108-amino-acid #biologically inactive prohormone, proBNP Further cleavage of proBNP results in a physiologically active 32-amino- acid peptide BNP and a biologically inert 76-amino-acid peptide N-terminal proBNP (NT-proBNP) [2].

For more articles on BJSTR Journal please click on https://biomedres.us/

For more Immunological Diseases Articles on BJSTR

https://biomedres.us/fulltexts/BJSTR.MS.ID.001606.php

Therapeutic Effects of BNP in Heart Failure, Good or Bad? by Dongye Li in BJSTR